Sign in Subscribe

Archive

A collection of 370 issues

Latest

Non-Neutropenic Enterocolitis Risk Identified in Adjuvant CAPOX Therapy

Skip to content The CRC Digest ◇ RESEARCH Non-Neutropenic Enterocolitis Risk Identified in Adjuvant CAPOX Therapy A study examined the incidence and risk factors of non-neutropenic enterocolitis—a potentially serious side effect—in colorectal cancer patients receiving adjuvant capecitabine and oxaliplatin chemotherapy. (Clinical Colorectal Cancer) This content is informational only and

CRC Research Update — July 24, 2026

Today's colorectal cancer research highlights

MSI-H/dMMR Prevalence Documented in Japanese CRC Registry

Skip to content The CRC Digest MSI-H/dMMR Prevalence Documented in Japanese CRC Registry A multicenter study of 1,464 Japanese patients with primary colorectal cancer enrolled from April 2024 to March 2025 investigated the frequency and features of MSI-H/dMMR tumors to support personalized treatment strategies. (Annals of Gastroenterological

Metastatic CRC Diagnosed Before Age 35 May Be a Distinct Subset

Skip to content The CRC Digest Metastatic CRC Diagnosed Before Age 35 May Be a Distinct Subset An Australasian registry study compared demographic and clinicopathologic characteristics of metastatic colorectal cancer patients diagnosed before age 35 with those diagnosed at 35–49 years and ≥50 years. (International Journal of Cancer) This

Circulating Tumor DNA Test Evaluated for Predicting Stage III Recurrence

Skip to content The CRC Digest ♥ LIVING WITH CRC Circulating Tumor DNA Test Evaluated for Predicting Stage III Recurrence The α-CORRECT study evaluated a blood test for circulating tumor DNA in patients with stage III colorectal cancer after surgery and chemotherapy to detect tiny traces of cancer that may signal

Patient Navigation Boosts Colonoscopy Completion After Positive Stool Tests

Skip to content The CRC Digest ▪ SCREENING Patient Navigation Boosts Colonoscopy Completion After Positive Stool Tests A quality improvement initiative at Cleveland Clinic used patient navigators to contact adults aged 45–75 with positive stool-based tests who had not completed colonoscopy within 360 days, aiming for ≥80% completion within 6

Vactosertib Plus Pembrolizumab Shows Manageable Safety in Non-MSI-High mCRC

Skip to content The CRC Digest ◆ TRIAL DATA Vactosertib Plus Pembrolizumab Shows Manageable Safety in Non-MSI-High mCRC A phase Ib/IIa study of vactosertib combined with pembrolizumab in non-MSI-high metastatic colorectal cancer demonstrated a manageable safety profile, with secondary outcomes including objective response rate, progression-free survival, and overall survival. (Nature

Cetuximab Rechallenge Tested Against Regorafenib in RAS Wild-Type mCRC

Skip to content The CRC Digest ◆ TRIAL DATA Cetuximab Rechallenge Tested Against Regorafenib in RAS Wild-Type mCRC A single-center randomized trial evaluated cetuximab plus irinotecan rechallenge versus regorafenib in RAS wild-type, microsatellite-stable metastatic colorectal cancer patients who had previously responded to then progressed off cetuximab, with progression-free survival as the

CRISPR Screens Reveal How MSI-H Tumors Depend on WRN Helicase

Skip to content The CRC Digest ◇ RESEARCH CRISPR Screens Reveal How MSI-H Tumors Depend on WRN Helicase Genome-wide CRISPR screens identified SMARCAL1 as a key modulator of WRN dependency in MSI-H colorectal cancer, with loss of SMARCAL1 rendering cells resistant to the WRN inhibitor HRO761. The findings shed light on

Review highlights accessible blood-based biomarkers for CRC detection

Skip to content The CRC Digest ◇ RESEARCH Review highlights accessible blood-based biomarkers for CRC detection A systematic review synthesizes circulating transcriptomic and proteomic biomarkers detectable by widely available RT-PCR and ELISA platforms, aiming to bridge the gap between high-throughput research and clinically scalable diagnostics. (Crit Rev Clin Lab Sci) This